Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0

Pregnancy Clinical Trial

— MOMSto40BMI  

Official title:

Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02509377
• Other study ID #: 24890
• Status: Terminated
• Phase: N/A
• Start date: July 2015
• Est. completion date: May 2017

Study information

• Verified date: June 2017
• Source: St. Louis University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Inclusion and exclusion criteria for fetal repair of MMC was established by the Management of Myelomeningocele Study (MOMS Trial) and these criteria are the standard of care throughout the United States. These criteria state exclusion for hypertension and diabetes which are known co-morbidities for obesity. Investigators plan to expand one exclusion criteria for open fetal repair surgery. Currently, an exclusion factor is a maternal BMI of 35.0 and greater.Investigators will maintain all other inclusion and exclusion criteria (including excluding for hypertension and diabetes) with the exception of expanding the BMI to include mothers with a BMI of 35.0 to 40.0. Co-morbidities of the research group will be compared to the comorbidities of the mothers published in the MOMS trial.

Description:

The MOMS trial proved prenatal repair of myelomeningocele was an advantage over postnatal repair for the fetus/neonate/child and is the standard of care for maternal/fetal dyads who meet the inclusion exclusion criteria. Investigators plan to maintain all inclusion exclusion criteria for open fetal repair surgery of myelomeningocele with one exception, the expansion of the maternal BMI to 40.0. This population of mothers with a BMI of 35.0 to 40.0 have not been studied. The morbidities of these mothers will be compared to morbidities of mothers with a BMI less than or equal to 34.9 currently in the scientific literature.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Maternal BMI 35.0 to 40.0

• No maternal documented co-morbidities

• Fetal MMC begins between thoracic 1 and sacral 1, on the spinal column.

• Evidence of fetal hindbrain herniation (hindbrain is being pulled down the spinal column).

• A gestational age is between 19 weeks 0 days and 26 weeks with evidence of placental membrane fusion.

• Documented normal fetal karyotype.

Exclusion Criteria:

• History of maternal alloimmunization problem

• Kell sensitization

• Risk of preterm birth

• History of spontaneous preterm birth

• Cervix <20mm in length

• Presence of cerclage

• Placental problem

• History of placental abruption

• Placental Previa

• Body-mass index of 40.1 or more

• Maternal contraindication to surgery

• Insulin-dependent pregestational diabetes

• Hypertension or preeclampsia

• HIV, hepatitis-B, or hepatitis-C positive

• Other medical condition of risk to mother

• Uterine problem

• Previous hysterotomy in the active uterine segment

• Severe fibroids

• Uterine malformation (bicornuate, arcuate, unicornuate, didelphys)

• No support person for periprocedural period

• Inadequate support at home for pregnancy

• Inadequate understanding of risks and benefits of fetal surgery

• Inability to comply with medical restrictions, follow up after fetal surgery

• Multiple gestation pregnancy (twins, triplets, etc.)

• A fetal anomaly unrelated to myelomeningocele (heart defect, lung lesions)

• Severe fetal kyphosis >30 degrees (curvature of the back)

Related Conditions & MeSH terms

• Meningomyelocele
• Myelomeningocele
• Pregnancy

Intervention

Procedure:
• Open Fetal Repair of Myelomeningocele
Open Fetal Repair of Myelomeningocele when mothers BMI is elevated

Locations

Country	Name	City	State
United States	SSM Cardinal Glennon Fetal Care Institute	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
St. Louis University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, Howell LJ, Farrell JA, Dabrowiak ME, Sutton LN, Gupta N, Tulipan NB, D'Alton ME, Farmer DL; MOMS Investigators. A randomized trial of prenatal versus postnatal repair of myelomeningocele. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Co-morbidities in mothers having fetal MMC repair	Measure the co-morbidity of mothers with a BMI of 35.0 to 40.0. Compare to published data in the MOMS trial.	up to 40 weeks